Optimizing the generation of recombinant single-chain antibodies against placental alkaline phosphatase

Hybridoma

Volumn 25, Issue 4, 2006, Pages 181-192

  Sheikholvaezin, Ali ^a   Sandström, Per ^a   Eriksson, David ^a   Norgren, Niklas ^a   Riklund, Katrine ^a   Stigbrand, Torgny ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; AMINO ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY H7; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; THIOREDOXIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ARTICLE; BACTERIAL STRAIN; DEVICE; DISULFIDE BOND; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EVALUATION; HIGH TEMPERATURE; HYBRIDOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PURIFICATION; PROTEIN STABILITY; SEQUENCE ANALYSIS; SOLUBILITY; TEMPERATURE SENSITIVITY;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 33751017388     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2006.25.181     Document Type: Article

References (55)

1. Riethmuller G, Schneider-Gadicke E, and Johnson JP: Monoclonal antibodies in cancer therapy. Curr Opin Immunol 1993;5:732-739.
2. Colcher D, Pavlinkova G, Beresford G, Booth BJ, and Batra SK: Single-chain antibodies in pancreatic cancer. Ann NY Acad Sci 1999;880:263-280.
3. Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50:814s-819s.
4. Clauss MA and Jain RK: Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res 1990;50: 3487-3492.
5. Yokota T, Milenic DE, Whitlow M, and Schlom J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-3408.
6. Maloney DG, Donovan K, and Hamblin TJ: Antibody therapy for treatment of multiple myeloma. Semin Hematol 1999;36:30-33.
7. Kipriyanov SM, Moldenhauer G, and Little M: High level production of soluble single chain antibodies in small-scale Escherichia coll cultures. J Immunol Methods 1997;200:69-77.
8. Ramm K, Gehrig P, and Pluckthun A: Removal of the conserved disulfide bridges from the scFv fragment of an antibody: effects on folding kinetics and aggregation. J Mol Biol 1999;290:535-546.
9. Nieva L, Honegger A, Krebber C, and Pluckthun A: Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng 1997:10:435-444.
10. Arndt KM, Muller KM, and Pluckthun A: Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. Biochemistry 1998;37:12918-12926.
11. Pluckthun A, Krebber A, Krebber C, Horn O, Knupfer O, Wenderoth R, Nieba L, Proba K, and Riesenberg D: Producing antibodies in Escherichia coli: from PCR to fermentation. In: Antibody engineering, McCfferty J, Hoogenboom HR, and Chiswell DJ (Eds.). IRL Press, Oxford, 1996, pp. 203-252.
12. Hudson PJ: Recombinant antibody fragments. Curr Opin Biotechnol 1998;9:395-402.
13. Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, and Pluckthun A: High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res 1999;59:5758-5767.
14. Brinkmann U, Di Carlo A, Vasmatzis G, Kurochkina N, Beers R, Lee B, and Pastan I: Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation. J Mol Biol 1997;268:107-117.
15. Baneyx F: Recombinant protein expression in Escherichia coli. Curr Opin Biotechnol 1999;10:411-421.
16. Marston FA: The purification of eukaryotic polypeptides synthesized in Escherichia coll. Biochem J 1986;240:1-12.
17. di Guan C, Li P, Riggs PD, and Inouye H: Vectors that facilitate the expression and purification of foreign peptides in Escherichia coli by fusion to maltose-binding protein. Gene 1988;67:21-30.
18. Smith DB and Johnson KS: Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 1988;67:31-40.
19. Butt TR, Jonnalagadda S, Monia BP, Sternberg EJ, Marsh JA, Stadel JM, Ecker DJ, and Crooke ST: Ubiquitin fusion augments the yield of cloned gene products in Escherichia coli. Proc Natl Acad Sci USA 1989;86:2540-2544.
20. LaVallie ER, DiBlasio EA, Kovacic S, Grant KL, Schendel PF, and McCoy JM: A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. Biotechnology (NY) 1993;11:187-193.
21. Ahlstrom KR, Hietala SO, Stendahl U, and Stigbrand T: Radioimmunodetection of ovarian cancer. Acta Oncol 1993;32:729-734.
22. 131I-labeled anti-PLAP monoclonal antibodies. Acta Radiol 1991;32:375-380.
23. Stigbrand T, Hietala SO, Johansson B, Makiya R, Riklund K, and Ekelund L: Tumour radioimmunolocalization in nude mice by use of antiplacental alkaline phosphatase monoclonal antibodies. Tumour Biol 1989;10:243-251.
24. Millan JL and Stigbrand T: Antigenic determinants of human placental and testicular placental-like alkaline phosphatases as mapped by monoclonal antibodies. Eur J Biochem 1983;136:1-7.
25. Le Du MH, Stigbrand T, Taussig MJ, Menez A, and Stura EA: Crystal structure of alkaline phosphatase from human placenta at 1.8 Å resolution. Implication for a substrate specificity. J Biol Chem 2001;276:9158-9165.
26. Ullen A, Nilsson B, Ahlstrom KR, Makiya R, and Stigbrand T: In vivo and in vitro interactions between idiotypic and antiidiotypic monoclonal antibodies against placental alkaline phosphatase. J Immunol Methods 1995;183:155-165.
27. Sandstrom P, Johansson A, Ullen A, Rathsman S, Riklund-Ahlstrom K, and Stigbrand T: Idiotypic-anti-idiotypic antibody interactions in experimental radioimmunotargeting. Clin Cancer Res 1999;5:3073s-3078s.
28. Orlandi R, Gussow DH, Jones PT, and Winter G: Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA 1989;86:3833-3837.
29. Marchuk D, Drumm M, Saulino A, and Collins FS: Construction of T-vectors, a rapid and general system for direct cloning of unmodified PCR products. Nucleic Acids Res 1991;19:1154.
30. Sandstrom P, Johansson A, Ullen A, Behravan G, and Stigbrand T: Differences in sequence and affinity between three monoclonal anti-idiotypic antibodies against one anti-placental alkaline phosphatase idiotypic antibody. Tumor Targeting 1998;3:80-86.
31. th ed. NIH publication no. 91-3242. National Institutes of Health, Washington, DC, 1991.
32. Brinkmann U, Reiter Y, Jung SH, Lee B, and Pastan I: A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci USA 1993;90:7538-7542.
33. Kobayashi H, Han ES, Kim IS, Le N, Rajagopal V, Kreitman RJ, Pastan I, Paik CH, and Carrasquillo JA: Similarities in the biodistribution of iodine-labeled anti-Tac single-chain disulfide-stabilized Fv fragment and anti-Tac disulfide-stabilized Fv fragment. Nucl Med Biol 1998;25:387-393.
34. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
35. Bowden GA and Georgiou G: Folding and aggregation of beta-lactamase in the periplasmic space of Escherichia coli. J Biol Chem 1990;265:16760-16766.
36. Bourot S, Sire O, Trautwetter A, Touze T, Wu LF, Blanco C, and Bernard T: Glycine betaine-assisted protein folding in a lysA mutant of Escherichia coli. J Biol Chem 2000;275:1050-1056.
37. Barth S, Huhn M, Matthey B, Klimka A, Galinski EA, and Engert A: Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions. Appl Environ Microbiol 2000;66:1572-1579.
38. Kurucz I, Titus JA, Jost CR, and Segal DM: Correct disulfide pairing and efficient refolding of detergent-solubilized single-chain Fv proteins from bacterial inclusion bodies. Mol Immunol 1995;32: 1443-1452.
39. Chowdhury PS, Vasmatzis G, Beers R, Lee B, and Pastan I: Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv. J Mol Biol 1998;281: 917-928.
40. Huston JS, Levinson D, Mudgett-Hunter M, et al: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988;85:5879-5883.
41. Saul FA and Poljak RJ: Structural patterns at residue positions 9, 18, 67 and 82 in the VH framework regions of human and murine immunoglobulins. J Mol Biol 1993;230:15-20.
42. Whitlow M, Filpula D, Rollence ML, Feng SL, and Wood JF: Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv. Protein Eng 1994;7:1017-1026.
43. Worn A and Pluckthun A: Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. Biochemistry 1999;38:8739-8750.
44. Reiter Y, Brinkmann U, Lee B, and Pastan I: Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat Biotechnol 1996;14:1239-1245.
45. LaVallie ER, DiBlasio EA, Kovacic S, Grant KL, Schendel PF, and McCoy JM: A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. Biotechnology (NY) 1993;11:187-193.
46. Sachdev D and Chirgwin JM: Order of fusions between bacterial and mammalian proteins can determine solubility in Escherichia coli. Biochem Biophys Res Commun 1998;244:933-937.
47. Ayala M, Balint RF, Fernandez-de-Cossio L, Canaan-Haden JW, Larrick JW, and Gavilondo JV: Variable region sequence modulates periplasmic export of a single-chain Fv antibody fragment in Escherichia coli. Biotechniques 1995;18:832,835-838,840-842.
48. Desplancq D, King DJ, Lawson AD, and Mountain A: Multimerization behaviour of single-chain Fv variants for the tumour-binding antibody B72.3. Protein Eng 1994;7:1027-1033.
49. Huston JS, George AJT, Tai MS, MacCartney JE, Jin D, Segal DM, Keck P, and Oppermann H: Single-chain Fv design and production by preparative folding. In: Antibody Engineering, 2nd ed. Borrebaeck CAK (Ed.), Oxford University Press, New York, 1995, pp. 185-227.
50. Huston JS, Mudgett-Hunter M, Tai MS, McCartney J, Warren F, Haber E, and Oppermann H: Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol 1991;203:46-88.
51. Deonarain MP, George AJ, and Epenetos AA: Redesigned anti-human placental alkaline phosphatase single-chain Fv: soluble expression, characterization and in vivo tumour targeting. Protein Eng. 1997;10:89-98.
52. Knappik A and Pluckthun A: Engineered turns of a recombinant antibody improve its in vivo folding. Protein Eng 1995;8:81-89.
53. Kikuchi Y, Uno S, Nanami M, Yoshimura Y, Iida S, Fukushima N, and Tsuchiya M: Determination of concentration and binding affinity of antibody fragments by use of surface plasmon resonance. J Biosci Bioeng 2005;100:311-317.
54. 125I-labeled anticytokeratin and antiPLAP monoclonal antibodies. Anticancer Res 1991;11:555-560.
55. Åhlström R, Makiya R, Sundström B, Thornell L-E, and Stigbrand T: Radioimmunotherapy of HeLa cell tumors in nude mice by a combination of iodine-131-labelled monoclonal antibodies against placental alkaline phosphatase and cytokeratin. Tumor Targeting 1995;1:239-244.